在多发性骨髓瘤治疗中使用talquetamab
Lawrence Liu1, Amrita Krishnan2
1Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA. laliu@coh.org.
Haematologica
|October 19, 2023
概括
塔尔克塔马布是一种新的双特异性抗体,在复发性或耐火性多发性髓瘤中显示出有希望的疗效和耐久性. 与现有治疗方法相比,这种疗法提供了一种具有不同副作用概况的替代方案.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤仍然是一个重大挑战,特别是在复发或耐火病例中.
- 现有疗法存在局限性,需要新的治疗方法.
- 双特异性抗体代表了多发性骨髓瘤治疗的有希望的进步.
研究的目的:
- 报告talquetamab的第一阶段试验的初步结果.
- 评估talquetamab在复发性或耐火性多发性髓瘤患者的疗效和安全性.
- 为了比较talquetamab与现有的双特异抗体疗法.
主要方法:
- 一期临床试验. 一期临床试验.
- 塔尔基塔马布是一种针对GPRC5D和CD3.3的双特异性抗体.
- 治疗设置:复发性或耐火性多发性髓瘤的第四线或之后.
主要成果:
- 塔尔基塔马布的疗效和反应持续时间与特克利斯塔马布的疗效和反应持续时间相当.
- 与特克利斯塔马布相比,使用塔尔克塔马布观察到的感染较少.
- 发现了独特的特定类别的副作用,包括皮肤,口腔和指甲毒性.
结论:
- 塔尔克塔马布是一种高效且耐受性良好的治疗方法,用于重度预先治疗的多发性髓瘤.
- 它为复发性或耐火性多发性髓瘤的治疗选择提供了宝贵的补充.
- 显而易见的副作用概况需要仔细监测和管理.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K